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Summary Fifty-five consecutive patients with primary gastrointestinal intermediate or high grade non-
Hodgkin's lymphoma were analysed to assess the efficacy of chemotherapy following surgical tumour
resection. Histological subtypes were high grade (n=18), intermediate grade (n=36) and unclassified (n=l).
The majority of patients had gastric presentation (71%) and localised disease (84%). Surgery consisted of
radical resection in 25 patients (45%) and partial or palliative excision in the remaining cases (22 and 8
respectively). Four subjects died within 3 months of surgery, two patients refused adjuvant chemotherapy and
49 completed the postoperative chemotherapeutic programme. Chemotherapy included either Fi2/74 (adria-
mycin +vincristine+bleomycin+cyclophosphamide+prednisone) or Fi3/74 (adriamycin+VM26+bleo-
mycin +cyclophosphamide +prednisone). Excluding the group who underwent radical tumour resection,
postoperative chemotherapy induced complete remission in 81% of the remaining 30 patients. The 10-year
cause-specific survival for the 53 treated patients was 76% (median follow-up 58 months) with a stable curve
plateau after 80 months. Proportional-hazard multivariate statistics showed that survival was influenced by
type of surgical resection (P<0.05) and stage (P<0.05), whereas age, sex and histological subtype were not
influential. Our data indicate that chemotherapy following surgical resection of gastrointestinal lesion induces
long-term remission in primary gastrointestinal lymphomas.
Non-Hodgkin's lymphomas (NHLs) are known to arise from
extranodal sites with an estimated frequency of 10-30%
(Banfi et al., 1968; Freeman et al., 1972; Jones et al., 1973;
Rudders et al., 1978; Reddy et al., 1980; Ho et al., 1984;
Gospodarowicz et al., 1987). The gastrointestinal tract is the
site most frequently affected at diagnosis accounting for
about 4-18% of all extranodal forms of NHLs (Freeman et
al., 1972; Reddy et al., 1980; Ho et al., 1984; Lewin et al.,
1978; Isaacson et al., 1979; Herrmann et al., 1980; Hande et
al., 1978; Strauss et al., 1983; Gospodarowicz et al., 1983;
Siegert et al., 1985; Carnevali et al., 1987). While several
studies have emphasised the effectiveness of the complete
surgical resection of localised lesions (Siegert et al., 1985;
Fleming et al., 1982; Maor et al., 1984; Paulson et al., 1983),
the majority of authors consider this therapeutic approach as
non-curative. The clinical efficacy of adjuvant postoperative
radiotherapy remains controversial (Herrmann et al., 1980;
Hande et al., 1978; Gospodarowicz et al., 1983; Siegert et al.,
1985; Paulson et al., 1983; Weingrad et al., 1982; Lim et al.,
1977; Shimm et al., 1983; Herrera et al., 1985; Dragosics et
al., 1985; Rao et al., 1984; Mittal et al., 1983; Ampil, 1987).
In some investigations, chemotherapy alone (Hande et al.,
1978; Siegert et al., 1985; Paulson et al., 1983; Rosenfelt &
Rosemberg, 1980; Sheridan et al., 1985; Liang et al., 1987;
Shepherd et al., 1988) or combined with radiotherapy (Maor
et al., 1984; Paulson et al., 1983; Herrera et al., 1985;
Economopulos et al., 1985; Liang et al., 1987; Omar et al.,
1985; Steward et al., 1985) have ensured improved survival
rates. However, it is generally agreed that the role of
chemotherapy in localised NHL also requires further study.
The present investigation was conducted in a large series
of consecutive untreated patients with primary gastro-
intestinal NHL of intermediate or high grade histological
subtype in order to evaluate factors influencing prognosis
and to assess the efficacy of two original chemotherapeutic
protocols combined with surgical resection.
Patients and methods
In a series of 516 consecutive NHLs observed at the Division
of Haematology (Florence) from 1 March 1974 to 31
Received 17 August 1988, and in revised form, 8 March 1989.
December 1986, 55 cases of untreated primary gastro-
intestinal NHL of intermediate or high grade (11%) were
diagnosed and formed, with no exclusion, the population
studied herein (median age=55 years, range 10-79).
Diagnosis of primary gastrointestinal NHL was made by
the criteria reported by Lewin et al. (1978). Diagnostic
specimens were obtained in 54 patients by surgical resection
of one or more sites of the gastrointestinal tract, and in one
patient by endoscopic biopsy. All biopsies and surgical
specimens were reviewed and classified according to both the
modified Rappaport classification (Rappaport, 1966) and the
Working Formulation (NHL Pathologic Classification
Project, 1982). Clinico-pathological data were obtained from
all patients, but only 53 cases could be evaluated for the
response to therapy because two patients refused chemo-
therapy. The median follow-up period was 58 months (range
1-146 months). Two patients were lost tQ follow-up, while
the remaining 53 were followed until death or until 31
December 1987.
Patients were staged according to the Ann Arbor staging
system (Carbone et al., 1971) as modified for stage II by
Musshoff & Schmidt-Vollmer (1975). Weight loss was not
considered as a constitutional symptom (Maor et al., 1984).
All patients were evaluated by history and physical examin-
ation, blood counts, liver function tests, chest and gastro-
intestinal X-ray, abdominal CT scan or ultrasonography,
and bone marrow biopsy. Exploratory laparotomy was per-
formed in 54 patients.
The extent of resection was defined as radical or not
according to the surgical charts and the histological evalu-
ation of resected specimens. Non-radical excisions were
classified as partial, when the residual mass after surgery was
less than or equal to Scm in diameter (small residual bulky
disease), or palliative when it exceeded this value (large
residual bulky disease). In four patients a second operation
was performed because of inadequate surgical staging.
The Fi2/74 or the Fi3/74 chemothferapeutic protocols
(Bellesi et al., 1976, 1982) were administered to patients with
DPDL or DH, respectively. Fi2/74 is based on the adminis-
tration of adriamycin (40mgm-2) on day 1, vincristine
(1mgm-2) on days 2 and 9, bleomycin (10mgm-2) on days
2, 3, 9 and 10, cyclophosphamide (300mgm-2) on days 4, 5,
11 and 12, prednisone (40mgm-2) on days 3-12. Fi3/74 is
identical to Fi2/74 except that vincristine is replaced by
VM26 (50mgm-2) on the same days of the protocol.
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Combination chemotherapy was administered every 21 days.
The response to treatment was evaluated by standard
criteria.
Statistical analysis for contingency tables included Fisher's
exact test for 2 x 2 tables and the x2 test. Survival was
measured from the date of diagnosis to either the end of
follow-up or the date of death. In cause-specific curves, only
deaths caused by lymphoma were considered (including
postoperative deaths); patients who died of causes unrelated
to disease were considered alive at the time of death. The
length of disease-free survival was calculated from the date
of response to either the end of follow-up or the date of
relapse; patients who failed to achieve complete remission
(CR) were considered as relapsed at time zero. Survival
curves were plotted by actuarial methods and compared by
univariate log rank statistics (Peto et al., 1977). Multivariate
analysis of survival and disease-free data was carried out
using Cox's proportional hazard model (Cox, 1972). The
analysis was performed using the step-down method with
statistical level set at P<0.05.
Results
Clinico-pathological findings
Fifty-five patients with primary gastrointestinal NHL were
evaluated, representing 11% of all cases of NHL diagnosed
from March 1975 to December 1986. The patients' charac-
teristics are summarised in Tables I and II.
The median age at presentation of gastric, intestinal and
multiple-site cases was 51, 52 and 49 years, respectively; the
patients with ileocecal localisation were slightly younger
(median age=40 years, range 10-62). No association was
found in the distribution of cases by histological subtype,
stage and site of involvement.
Table I Clinico-pathological characteristics of 55 patients














































Radical tumour resection with curative intent was performed
in 23 patients (with gastric (n= 19) or intestinal (n=4)
localisation), while partial and palliative operations were
performed, respectively, in 22 cases (16 gastric and 6 intesti-
nal) and eight cases (3 gastric, 2 intestinal and 3 multiple-site
forms). Two patients who underwent radical resection
refused chemotherapy and so cannot be evaluated.
Forty-nine patients completed the chemotherapeutic proto-
col receiving a median of three cycles (range 3-8). The
remaining patients refused chemotherapy (n=2) or died
postoperatively (n=4). Patients in documented CR discon-
tinued chemotherapy after a minimum of three cycles; those
patients who did not achieve CR after three cycles were
given another three courses of the same or an alternative
regimen. No patient in this study received radiotherapy.
Response to therapy
The response to therapy could be evaluated in 49 cases
(Table III). Forty-four subjects achieved CR (90%), four
(8%) had only a partial remission (PR) and one (2%) had
no response (NR). Stage (I-II vs IV) was a statistically
significant prognostic factor for the achievement of CR
(P<0.001 by Fisher's test). The residual bulk after surgery
was a significant factor because the CR rate was 95% after
partial resection compared with 43% after palliative resec-
tion (P<0.05 by Fisher's test). The achievement of CR was
not influenced by sex, age, histology or site of involvement.
Three of the 44 subjects who achieved CR relapsed within
24-36 months. At the present time, two patients are under
therapy and one has died.





















n n(%) n(%) n(%)
49 44 (90) 4 (8) 1 (2)
26 24 (92) 2 (8)
23 20 (87) 2 (9)
33 31 (94) 2 (6)




32 (94) 2 (6)
12(100) -
- 2(67)
41 40 (98) 1 (2)



















Table II Histological subtype of 53 patients with primary gastrointestinal NHL
n %
Rappaport classification
Diffuse histiocytic 18 33
Diffuse lymphocytic poorly differentiated 36 65
Unclassified 1 2
Working formulation
Intermediate grade E: diffuse, small cleaved 10 18
F: diffuse, mixed small and large cell 13 23
G: diffuse, large cell 13 23
High grade H: diffuse, large cell, immunoblastic 16 30
I: diffuse, lymphoblastic 1 2
J: diffuse, small non-cleaved cell 1 2
U: unclassified 1 2246 G. BELLESI et al.
Survival
The overall actuarial survival for the 53 evaluable patients
was 78% at 5 years and 65% at 10 years, including all
causes of death. The cause-specific survival in the same
population was 80% at 5 years and 76% at 10 years (Figure
1). Of interest is the fact that the cause-specific and the
disease-free actuarial curves both showed a long-lasting
plateau after the initial small series of treatment failures.
The multivariate survival analysis (Table IV) identified
three variables influencing survival at significant levels: res-
ponse to treatment, extent of surgical resection, and stage.
The response to the combined treatment was the most
important prognostic variable: the cause-specific survival of
complete responders (96% at 5 years, 91% at 10 years) was
significantly better than that of patients who had a partial
response or no response (22% at 5 years; P<0.001 by log
rank test). The influence of tumour resection on survival is
illustrated in Figure 2: the actuarial curve of patients under-
going palliative surgery was worse than the two curves of
radically resected patients (P<0.01 by log rank test) and of}
patients treated with partial resection (P<0.10 by log rank
test). Finally, the disease extension at presentation, as mea-
sured by stage, was also found to influence survival: the
cause-specific actuarial curve of patients with localised dis-
ease (stage I-II; 10-year survival rate of 95%) was signi-
ficantly better than the curve of stage IV patients (10-year
survival rate of 50%; P<0.05 by log rank test). Sex, age,
histological subtype and site of gastrointestinal involvement
had no significant effect on survival.
As regards the relapse-free survival (Figure 1), the overall
rate for the 53 patients was 75% at 10 years with a median
survival exceeding 142 months. The multivariate analysis
(Table IV) indicated that the type of surgical resection and
the stage significantly affected the length of the disease-free
interval. The relapse-free survival was not influenced by sex,
age, histology or site of gastrointestinal involvement.
Two patients who were treated with surgery alone due to
refusal of chemotherapy (both of stage I, age 10 and 78
years) are alive and disease-free at 4 and 7 years,
respectively.
Complications
Two patients died of causes possibly related to chemo-
therapy (heart failure and hepatic necrosis). Neither gastro-
intestinal perforation nor bleeding was observed. A second
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Figure 1 Actuarial curves of survival in the overall population
(dashed line, n =55), cause-specific survival (solid line), and
disease-free survival (dotted line) in the 53 evaluable patients.
The end of individual follow-up periods is indicated by vertical
tick marks whose height is proportional to the number of
subjects (minimum height = 1 case).
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Figure 2 Cause-specific survival according to the extent of
surgical resection (solid line, radical resection, n=23; dashed line,
partial resection, n =22; dotted line, palliative resection, n = 8).
Table IV Multivariate Cox analysis of variables influencing survival and freedom from relapse at P level of
0.05
Survival Freedom from relapse
(n=53) (n =47)
Relative risk Relative risk
(95% confidence (95% confidence
Variablea P interval) P interval)
Response to treatment 0.0002 n.a. n.a.
PR or NR 89.7(8.4-961)
Type of surgical resection 0.03 0.01
Partial resection 4.4(0.5-38) 16.3(3.4-78)
Palliative resection 15.8(1.7-148) 26.3(5.0-136)
Stage 0.04 0.05
Stage IV 31.6(1.2-952) 6.1(1.1-30)
Sex n.s. - n.s.
Histotype n.s. - n.s.
Age n.s. - n.s.
Site of gastrointestinal disease n.s. - n.s.
aIn accordance with statistical model, relative risk and 95% confidence interval are indicated only for
second level (and third level when applicable) of each variable compared with first level (relative risk= 1); first
levels are not shown and are CR, radical resection, and stage I or II for the three significant variables,
respectively. Abbreviations: n.s., not significant; n.a., not applicable.
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Discussion
In recent times, the role of surgery in the management of
gastrointestinal lymphomas has gained increasing importance
not only to ensure a correct histological diagnosis and an
accurate pathological staging, but also because the tumour
resection has proved to have a clearly significant impact on
patients' survival (Gospodarowicz et al., 1983; Fleming et
al., 1982; Paulson et al., 1983; Herrera et al., 1985; Dragosics
et al., 1985; Ampil, 1987; Rosenfelt & Rosemberg, 1980;
Economopoulos et al., 1985; Sheridan et al., 1985; Liang et
al., 1987; Steward et al., 1985; Janus et al., 1984; List et al.,
1988; Shepherd et al., 1988).
Our study indicates that chemotherapy following surgical
resection of gastrointestinal lymphomas is highly effective:
we obtained 81% CRs in patients treated with partial or
palliative resection, and an overall 76% 10-year cause-
specific survival, which are results comparable with those of
other recently published reports (Paulson et al., 1983;
Sheridan et al., 1985; Liang et al., 1987; Janus et al., 1984;
List et al., 1988; Shepherd et al., 1988). The extent of
tumour resection was a major determinant of prognosis in
our patients and was unequivocally identified by the multi-
variate analysis of survival and disease-free data. Probably,
the better prognosis of resected patients depends not only on
the presence of a smaller post-operative tumour mass, but
also on the lower rate of gastrointestinal perforation or
haemorrhage, which are rather frequent complications of
non-resected lymphomas (Hande et al., 1978; Fleming et al.,
1982; Weingrad et al., 1982; Liang et al., 1987; Naqvi et al.,
1969). We had no such complication during chemotherapy,
in keeping with several previous reports using a chemothera-
peutic treatment (Paulson et al., 1983; Sheridan et al., 1985;
Liang et al., 1987; Janus et al., 1984).
The frequency of recurrent extra-abdominal disease in
patients in stage I or II treated with surgery alone or
combined with radiotherapy is known to be relatively high,
ranging from 14 to 55% (Weingrad et al., 1982; Shim et al.,
1983; Mittal et al., 1983; Dworkin et al., 1982; Bettini et al.,
1983). This relapse rate seems to be lower in patients treated
with chemotherapy (Paulson et al., 1983; Economopoulos et
al., 1985; Sheridan et al., 1985; Janus et al., 1984; Shepherd
et al., 1988). Hence, our findings (e.g. 74% disease-free at 10
years for stage II2) provide support for the concept that the
chemotherapeutic treatment reduces the frequency of recur-
rent extra-abdominal disease in stages I and II, underscoring
the role of systemic chemotherapy in localised cases.
The prolonged disease-free survival of two patients in
stage I who refused chemotherapy may raise the question of
whether systemic chemotherapy is also needed in cases where
the surgical resection appears to be complete. Although
specific controlled studies in this area are lacking, a compre-
hensive evaluation of the data published so far (Lim et al.,
1977; Bertini et al., 1987; Connors & Wise, 1974; Contreary
et al., 1980; Caraveo et al., 1979; Dworkin et al., 1982;
Paulson et al., 1983; Economopoulos et al., 1985; Sheridan
et al., 1985; Janus et al., 1984; Shepherd et al., 1988)
supports the thesis that combined surgery and chemotherapy
are superior to surgery alone. Hence, the recommendation to
administer at least three cycles of chemotherapy, even after
radical surgery, in our view is justified, at least until a
controlled clinical trial demonstrates the contrary.
Our study shows that the prognosis of patients who fail to
achieve CR is extremely poor and that there seems to be no
effective second-line therapy. This fact makes the primary
treatment selection a very important decision. In the light of
these data, the recently proposed aggressive third-generation
chemotherapeutic protocols (Fisher et al., 1987) seem to be
indicated for patients with large residual bulk after surgery,
who are known to have a poor prognosis (as confirmed by
our findings). In conclusion, the results of our study are of
interest because a relatively large series of patients was
examined and because the duration of their follow-up was
adequate; considering the single-centre nature of our study
and the homogeneity of the chemotherapeutic approach
adopted, our data may provide a useful reference point for
further studies in this area.
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